10.1158@1535 7163.MCT 20 0406

Author Manuscript Published OnlineFirst on December 9, 2020; DOI: 10.1158/1535-7163.
MCT-20-0406
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Title Page:
ABBV-085, antibody-drug conjugate targeting LRRC15, is effective in osteosarcoma: A
report by the Pediatric Preclinical Testing Consortium
Authors: Pooja Hingorani1, Michael E. Roth1, Yifei Wang1, Wendong Zhang1, Jonathan D.
Gill1, Douglas J. Harrison1, Beverly Teicher2, Stephen Erickson3, Gregory Gatto3, Malcolm A.
Smith2, Edward A. Kolb4, Richard Gorlick1*
1. Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX,

77030
2. Cancer Therapeutics Evaluation Program, National Cancer Institute, Bethesda, MD 20892
3. Global Health Technologies, RTI International
4. Division of Pediatric Hematology/Oncology, Nemours/Alfred I. duPont Hospital for
Children, Wilmington, DE 19803
Short Running Title- Activity of ABBV-085 in osteosarcoma
Keywords
OS Osteosarcoma
PPTC Pediatric Preclinical Testing Consortium
PDX Patient Derived Xenograft
*Corresponding Author:
Richard Gorlick, MD
Mosbacher Chair and Division Head, Pediatrics
The University of Texas MD Anderson Cancer Center
Department of Pediatrics
Houston, TX 77030
Office Number: (713) 792-6620
Email: RGorlick@mdanderson.org
Conflict of Interest: The authors have no conflicts to report

Acknowledgements: Financial Support: This work was funded by the National Cancer
Institute’s grant 5U01CA199221-06
Downloaded from mct.aacrjournals.org on December 11, 2020. © 2020 American Association for Cancer Research.
Author Manuscript Published OnlineFirst on December 9, 2020; DOI: 10.1158/1535-7163.MCT-20-0406
Abstract
Membrane protein leucine-rich repeat containing 15 (LRRC15) is known to be expressed in
several solid tumors including osteosarcoma. ABBV-085, an antibody-drug conjugate against
LRRC15, conjugated to monomethyl auristatin E (MMAE) was studied in osteosarcoma patient
derived xenografts (PDX) by the Pediatric Preclinical Testing Consortium (PPTC). LRRC15
expression data was obtained from PPTC RNA sequencing data for the PDX models. The
TARGET database was mined for LRRC15 expression in human osteosarcoma. Protein
expression was confirmed via immunohistochemistry in three PDX models. Seven osteosarcoma
PDX models (OS1, OS9, OS33, OS34, OS42, OS55 and OS60) with varying LRRC15 gene
expression were studied. ABBV-085 was administered at 3mg/kg (OS33), 6 mg/kg (all 7 PDX)
and 12mg/kg (OS60) weekly for 4 consecutive weeks via intraperitoneal injection. Control
cohorts included vehicle and an isotype MMAE-linked antibody. Tumor volumes and responses
were reported using PPTC statistical analysis. OS1, OS33, OS42, OS55 and OS60 had high
LRRC15 expression while OS9 and OS34 had low LRRC15 expression. ABBV-085 inhibited
tumor growth in 6/7 PDX models as compared to vehicle control and significantly improved
event-free survival in 5/7 models as compared to isotype controls. Two models showed
maintained complete responses while all others showed progressive disease. Response correlated
with LRRC15 expression. ABBV-085’s antitumor activity against osteosarcoma PDX suggests
LRRC15 may be a rational target for pursuing clinical trials in patients with this disease.
Introduction
The outcome of patients with osteosarcoma (OS), both localized and metastatic, has not changed
for several decades since the advent of adjuvant chemotherapy 1. This is especially frustrating
given the tremendous advances that have occurred in the ability to analyze and understand its
2-4
very complex genome . Due to the lack of identification of recurrent targetable genetic
alterations in a large proportion of patients, these biologic discoveries have thus far not led to
significant therapeutic advancements. Thus, other strategies that are broadly applicable in OS are
needed to target this disease.
Membrane protein leucine-rich repeat containing 15 (LRRC15), a 581 amino acid Type 1
membrane protein with no obvious intracellular signaling domains, is highly expressed on cancer
associated fibroblasts in the stromal microenvironment of many solid tumors. In some tumors
such as sarcomas including OS, melanoma and glioblastoma, it is expressed both on stromal
fibroblasts as well as tumor cells 5. LRRC15 has limited expression in normal tissue and thus
may be an attractive target for drug therapy.
Antibody-drug conjugates (ADC) are a therapeutic strategy in which a cytotoxic payload is
attached to an antibody against a surface protein expressed on cancer and/ or cancer associated
stromal cells via a linker, with the goal of delivering the payload to these cells via antigen-
antibody interaction and internalization. The antibody, by targeting a specific cell population
enhances the therapeutic index and permits the delivery of drug doses that would otherwise be
too toxic with systemic administration 6.
ABBV-085 is an antibody drug conjugate (ADC) directed against LRRC15 that contains the
7, 8
tubulin inhibitor monomethyl auristatin E (MMAE) . Preclinical testing of ABBV-085 in rats
and cynomolgus monkeys have not shown any significant targeted toxicities at sites of normal
expression such as skin9. ABBV-085 has also been shown to be active against several adult
tumor xenografts such as non-small cell lung cancer, breast and glioblastoma multiforme as well
as against a multi-drug resistant OS xenograft when administered at dose of 6mg/kg every 4
days9. A recent phase 1 study of ABBV-085 in patients with advanced sarcoma demonstrated the
agent is well-tolerated and more than 50% of patients had a partial response (PR) or stable
disease. Two of the 10 OS patients enrolled on study had a PR 10.
In this study, the in vivo activity of ABBV-085 was assessed in a panel of OS PDX models with
high and low LRRC15 expression, as part of Pediatric Preclinical Testing Consortium (PPTC).
Materials and Methods
Pediatric Preclinical Testing Consortium Models
PPTC is an NCI-funded collaborative initiative that includes researchers within and outside
United States that contribute preclinical models and help evaluate new agents across a variety of
pediatric cancers. All of these models have been well validated through multiple different
technologies over the years and all of the current available data on these models including their
molecular and histologic characterization is in the public domain at PedcBioPortal

11-14
https://pedcbioportal.kidsfirstdrc.org/study/summary?id=pptc . Supplemental Table 1 lists
the passage number and growth characteristics of each of the tested xenografts.
LRRC15 expression analysis
The in vivo anticancer effects of ABBV-085 were assessed in a panel of seven OS models (OS1,
OS9, OS33, OS34, OS42, OS55 and OS60). PPTC xenograft RNA-seq data
(www.cBioPortal.org) was mined for LRRC15 mRNA expression. The panel of OS xenografts
selected for the study was based on the RNA expression data with the goal of including both
high and low expression models. In addition, LRRC15 protein expression was assessed in 3 of
the PDX models (OS9, OS33, OS60) via immunohistochemistry by Abbvie Inc. using the
LRRC15 antibody-Biotin: ABR, MouseIgG2a, Lot#17S56. Isotype antibody was used for
negative control. Staining was assessed by determining the intensity (0-3) as well as percentage
of positive cells and calculating an H score as previously described 15.
LRRC15 gene expression was also evaluated in human OS samples. RNA-seq data from 101 OS
patients was mined from the Therapeutically Applicable Research to Generate Effective
Treatments (TARGET) database (https://ocg.cancer.gov/programs/target). Further, OS tumor
LRRC15 expression data was compared with normal tissue RNA-sequencing data from the NIH
Genotype-Tissue Expression database (GTEx; https://www.gtexportal.org)
In vivo testing
ABBV-085 was provided by Abbvie Inc. (Chicago, IL). C.B.17SC scid-/- female mice were used
to propagate subcutaneous flank tumors. Ten mice were used in each control or treatment group.
First, ABBV-085 was tested at two doses of 6mg/kg and 12mg/kg administered via
intraperitoneal injection once per week for 4 consecutive weeks in two models with highest
LRRC15 expression (OS33 and OS60) to select appropriate dose for testing in all models. Then
all the remaining models were tested at 6mg/kg once per week for 4 weeks. OS33 underwent 2
sets of experiments – OS33-1 (initial dose finding) and OS33-2 (repeat 6mg/ kg and a lower dose
of 3mg/kg) to determine dose sensitivity. A control cohort that received vehicle and an
additional control cohort that received an isotype MMAE linked antibody were included in all
PDX models assessed. Tumor volumes were measured biweekly as previously described 11. All
mice were maintained under barrier conditions and experiments were conducted using protocols
and conditions in accordance with the Institutional Animal Care and Use Committee at M. D.
Anderson Cancer Center (ACUF Study #00001656-RN00).
The in vivo activity of ABBV-085 was evaluated using standard PPTC measures. Briefly, for
solid tumor experiments, an event is defined as a quadrupling of tumor volume from day 0. The
median time to event was assessed between the experimental and control cohorts. Differences in
event-free survival (EFS) between experimental groups (e.g., treated vs controls) were tested
with α = 0.05, two-sided alternative with ρ = 1, which is equivalent to the Peto & Peto
modification of Gehan-Wilcoxon. Objective responses reported as maintained complete
response, complete response, partial response, and stable disease were described for each model
as defined previously 11. Details of the statistical analysis methods are provided Appendix 1.
Results
LRRC15 expression in OS PDX models
We reviewed PPTC Agilent microarray gene expression data which showed overexpression of
LRRC15 for OS xenografts. The average LRRC15 gene expression value for non-OS/non-
glioblastoma multiforme xenograft lines was 35, while the OS xenograft expression values
ranged from 232 to 12,582 (Supplemental Table 2). Review of the RNA-seq data for PDX
models showed that OS1, OS33, OS42, OS55 and OS60 demonstrated high relative mRNA
expression compared with PDX models OS9 and OS42, with OS9 demonstrating the lowest
expression (Figure1A). LRRC15 protein expression was assessed in OS9, OS33, and OS60 and
mirrored the mRNA findings with minimal expression in OS9 and strong expression in OS33
and OS60. OS60 demonstrated the highest intensity (3/3) and greatest proportion of cells staining
positive (100%), whereas OS9 did not demonstrate any positive staining (Figure1B-D). H scores
were calculated for these three models (Figure 1E).
LRRC15 expression in human OS tumors
LRRC15 gene expression on human OS samples from TARGET database showed variable
expression levels in >90% of the samples with a median of 51.92 TPM (Figure 2A). Comparison
to normal human tissues showed significantly higher expression level in OS (median normal
tissue expression= 0.184 TPM; log fold change tumor versus normal = 4.36; p <0.01) (Figure
2B).
In vivo efficacy of ABBV-085
ABBV-085 was initially tested in 2 PDX models (OS33 and OS60) predicted to be responsive
due to high LRRC15 expression at doses 6mg/kg and 12mg/kg once per week for four weeks to
determine the optimal dose for testing in additional models. In addition, OS33 was also tested at
the lower dose of 3mg/kg. ABBV-085 at both 6 mg/kg and 12mg/kg significantly inhibited
tumor growth and prolonged EFS in the OS60 model compared to both the vehicle control
animals, with EFS T/C values > 4.0 and with PD2 objective responses. The isotype MMAE
control at 12 mg/kg did not significantly extend EFS compared to vehicle controls. In OS33,
ABBV-085 at both 6 mg/kg and 12 mg/kg was highly active with EFS T/C > 5.0, and with PR
and MCR objective responses, respectively. The isotype MMAE control at 12mg/kg showed
comparable levels of activity as ABBV-085 with an MCR suggesting non-specific activity of
payload in this model unrelated to LRRC15 at high doses. No significant weight loss was
observed in the treated mice and no mice experienced death due to toxicity. Details of these
testing results are provided in Table 1. Based on these studies, dose of 6mg/kg was selected for
testing in remaining models.
ABBV-085 significantly inhibited tumor growth at 6 mg/kg in 6/7 of the models tested compared
with the vehicle control cohorts (Table 1 and Figure 3A). OS9 was the only model that did not
demonstrate significantly delayed tumor growth compared to the vehicle control. We also
compared the response of ABBV-085 cohort to isotype MMAE antibody cohort. A difference in
tumor growth inhibition was seen in 3/7 models (OS1, OS33 and OS60) suggesting some non-
specific activity of isotype antibody in some of the OS models (Figure 3A). ABBV-085
treatment resulted in an objective response in 2/7 of models at 6 mg/kg, with OS33 and OS55
experiencing a maintained complete response (Figure 3A). All other models experienced
progressive disease with median time to event for treated versus control animals (EFS T/C)
ranging from 0.95 for OS9 to >4.65 for OS33. At 3mg/kg, ABBV-085 showed a PR in OS33
(Table 2).
OS33 was tested again at 6 mg/kg (OS 33-2), while results for OS-60 are from the initial dose-
finding experiments. In this second set of experiments with OS33 at 6mg/kg dose, a MCR was
observed. The discrepancy between the two sets of experiments is explained by the fact that in
the first experiment half of the mice in the test group achieved a CR and the other achieved PR,
therefore by PPTC convention, the response was reported as PR. In the second experiment, 2/ 10
mice had a PR and 8 had an MCR so the response was reported as MCR.
ABBV-085 treatment led to significantly prolonged EFS in 5/7 of these models compared with
the isotype control (Table 2 and Figure 3B). OS9 and OS34, the two models with the lowest
LRRC15 expression, were the only models that did not demonstrate significantly prolonged EFS
compared with the isotype control (Table 2 and Figure 3B).
Discussion
ABBV-085 exhibited significant antitumor activity against the PPTC OS PDX models with high
expression of LRRC15, demonstrated by prolonged EFS and objective responses. LRRC15 is
highly expressed on both cancer cells as well as tumor stroma of mesenchymal origin. High
LRRC15 expression is also seen in breast cancer, head and neck cancer, non-squamous cell lung
cancer and pancreatic cancer making it a potential target in a wide variety of solid tumors. The
mRNA expression is generally highly concordant with protein expression via IHC. Data suggests
16
that LRRC15 is a regulator of osteogenesis of mesenchymal stem cells . Further, presence of
LRRC15 expressing fibroblasts in tumor microenvironment portend a poor response to immune

17
checkpoint blockade . While LRRC15 mRNA expression in a large cohort of human OS
patients from the TARGET database is suggestive of strong expression in majority of the tumors,
additional studies establishing the prevalence of LRRC15 protein expression in OS patient
samples may be warranted. Our data provide proof of principle that LRRC15 may be a potential
target for antibody delivered cytotoxic payloads and worthy of further clinical trials.
ABBV-085 has entered clinical testing with a focus on patients with sarcomas 18. Following dose
escalation, an expansion cohort was evaluated using a dose of 3.6 mg/kg administered every two
weeks. Anticipated auristatin safety findings of ocular toxicity (may be related to the linker) and
peripheral neuropathy were observed. Other toxicities included fatigue and neutropenia. No
targeted toxicities at sites of normal LRRC15 expression such as skin were observed. Durable
responses were observed for relapsed refractory undifferentiated pleomorphic sarcoma (2
confirmed partial responses in 10 patients) and for OS (2 confirmed partial responses in 10
patients) providing essential human activity data for further OS specific trials.
ADCs are a relatively newer therapeutic approach in cancer therapy. ADCs comprise of an
antibody to a surface protein of interest such as LRRRC15, a linker and a payload cytotoxic
agent. The goal of an ADC is to be able to deliver large doses of the cytotoxic agent specifically
to the malignant cells that express the antigen without exposure to normal tissues. The
prerequisite characteristic for an effective ADC would not require the surface antigen to be
oncogenic although a dependency on the protein is preferable. ADC against oncogenic antigens
19
such as HER2 are being explored in OS . However, the antigen against which the ADC is
developed has to be present in a large proportion of OS tumors along with minimal expression in
normal tissues. If further study of LRRC15 expression in OS tumors confirms a strong
ubiquitous expression in majority of patient samples, it would make this protein an attractive
strategy for using the ADC approach to treat OS.
It is also important to consider what payload or cytotoxic agent the ADC is delivering and its
activity towards the tumor cells. Cytotoxic agents used as payloads include microtubule
inhibitors, topoisomerase inhibitors, and DNA damaging agents 6. The role of tubulin targeted
drug conjugates is not yet clear in OS, though there is preclinical evidence of target-specific
effects. However, other classes of cytotoxic agents such as DNA damaging agents may be more
20
relevant in the case of OS . One potential issue with using the ADC approach may be
development of resistance by downregulation of cell surface protein on the tumor cells, and this
would need to be monitored in preclinical and clinical studies. Nonetheless, identification of
novel surface proteins expressed on a majority of OS tumor cells and samples and developing
specific ADCs against them provides an exciting new therapeutic avenue in this disease.
10
References:
1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115: 1531-1543.
2. Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis
in pediatric osteosarcoma. Cell Rep. 2014;7: 104-112.
3. Poos K, Smida J, Maugg D, et al. Genomic heterogeneity of osteosarcoma - shift from single
candidates to functional modules. PLoS One. 2015;10: e0123082.
4. Kovac M, Blattmann C, Ribi S, et al. Exome sequencing of osteosarcoma reveals mutation signatures
reminiscent of BRCA deficiency. Nat Commun. 2015;6: 8940.
5. Purcell JW, Tanlimco SG, Hickson J, et al. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target
for Antibody–Drug Conjugates. Cancer research. 2018;78: 4059-4072.
6. Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, et al. Antibody-drug conjugates (ADCs) for cancer
therapy: Strategies, challenges, and successes. J Cell Physiol. 2019;234: 5628-5642.
7. Purcell J, Hickson J, Tanlimco S, et al. ABBV-085 is a novel antibody–drug conjugate (ADC) that targets
LRRC15 in the tumor microenvironment. European Journal of Cancer. 2016;69: S10.
8. Ben-Ami E, Huang Y, Gokhale PC, et al. LRRC15 is a novel antigen in sarcoma and the therapeutic
target of the antibody-drug conjugate (ADC) ABBV-085: AACR, 2018.
9. Purcell JW, Tanlimco SG, Hickson J, et al. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target
for Antibody-Drug Conjugates. Cancer Res. 2018;78: 4059-4072.
10. Demetri GD, Luke JJ, Hollebecque A, et al. First-in-human phase 1 study of ABBV-085, an antibody-
drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors: American Society
of Clinical Oncology, 2019.
11. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of
models and early testing results. Pediatr Blood Cancer. 2007;49: 928-940.
12. Geier B, Kurmashev D, Kurmasheva RT, Houghton PJ. Preclinical Childhood Sarcoma Models: Drug
Efficacy Biomarker Identification and Validation. Front Oncol. 2015;5: 193.
13. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel.
Clin Cancer Res. 2008;14: 4572-4583.
14. Rokita JL, Rathi KS, Cardenas MF, et al. Genomic Profiling of Childhood Tumor Patient-Derived
Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019;29: 1675-1689 e1679.
15. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell
lung carcinomas: correlation between gene copy number and protein expression and impact on
prognosis. J Clin Oncol. 2003;21: 3798-3807.
16. Wang Y, Liu Y, Zhang M, et al. LRRC15 promotes osteogenic differentiation of mesenchymal stem
cells by modulating p65 cytoplasmic/nuclear translocation. Stem Cell Res Ther. 2018;9: 65.
17. Dominguez CX, Muller S, Keerthivasan S, et al. Single-Cell RNA Sequencing Reveals Stromal Evolution
into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer
Discov. 2020;10: 232-253.
18. Demetri GD, Luke JJ, Hollebecque A, et al. First-in-human phase 1 study of ABBV-085, an antibody-
drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors. Journal of Clinical
Oncology. 2019;37: 3004-3004.
19. Takegawa N, Nonagase Y, Yonesaka K, et al. DS-8201a, a new HER2-targeting antibody-drug
conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer
T-DM1 resistance. Int J Cancer. 2017;141: 1682-1689.
11
20. Fu Y, Ho M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antib Ther.
2018;1: 33-43.
Table 1: Response to ABBV-085 at varying doses in two OS PDX models for dose finding
KM
EFS p-value minRTV minRTV Objective
Dose med EFS
Model Agent (days) T-C Gehan- mean±SD p-value Response
(mg/k) T/C
Wilcoxon Measure+
(days)
Vehicle
16.7 1.997±0.228 PD
Control
ABBV- p<
6 80.1 63.4 4.79 p < 0.001 1.022±0.167 PD2
OS-60 085 0.001
ABBV- p<
12 >86 >69.3 >5.14 p < 0.001 0.977±0.213 PD2
085 0.001
MMAE- p=
12 19.9 3.2 1.19 p = 0.024 1.634±0.347 PD1
antibody 0.023
Vehicle
15.6 1.990±0.264 PD
Control
ABBV- p=
6 >86 >70.4 >5.53 p < 0.001 0.117±0.138 PR
OS-33 085 0.001
ABBV- p=
12 >86 >70.4 >5.53 p < 0.001 0.080±0.148 MCR
085 0.001
MMAE- p=
12 >86 >70.4 >5.53 p <0.001 0.065±0.116 MCR
antibody 0.002
+ All the response measures are defined in Appendix 1
12
Table 2: Activity of ABBV-085 and isotype MMAE antibody vs. vehicle control for all PDX
models
KM
EFS p-value minRTV minRTV Objective
Dose med EFS
Model Agent (days) T-C Gehan- mean±SD p-value Response
(mg/k) T/C
Wilcoxon Measure+
(days)
ABBV- p<
6 72.6 47.4 2.88 p < 0.001 1.162±0.234 PD2
085 0.001
OS-1
MMAE- p=
6 32.5 7.3 1.29 p < 0.001 1.383±0.098 PD1
antibody 0.004
ABBV- p=
6 23.6 -1.2 0.95 p = 0.447 1.687±0.389 PD1
085 0.673
OS-9
MMAE- p=
6 23.4 -1.4 0.94 p = 0.631 1.684±0.268 PD1
antibody 0.370
ABBV- p<
6 > 84 > 65.9 > 4.65 p < 0.001 0.026±0.056 MCR
085 0.001
ABBV- p<
OS-33 3 81.4 63.4 4.51 p < 0.001 0.520±0.330 PR
085 0.001
MMAE- p=
6 29.4 11.3 1.62 p < 0.001 1.269±0.150 PD1
antibody 0.002
ABBV- p=
6 49.9 17.6 1.54 p < 0.001 1.136±0.113 PD1
085 0.001
OS-34
MMAE- p=
6 38.8 6.5 1.2 p = 0.025 1.233±0.121 PD1
antibody 0.052
ABBV- p=
6 25 4.8 1.24 p < 0.001 1.251±0.194 PD1
085 0.035
OS-42
MMAE- p=
6 21.3 1.1 1.06 p = 0.226 1.430±0.223 PD1
antibody 0.393
ABBV-
6 >168 >117.6 >3.34 p < 0.001 0.176±0.211 p <0.001 MCR
085
OS-55
MMAE-
6 151 101.1 3.01 p = 0.003 0.499±0.369 p<0.001 PR
antibody
ABBV- p<
6 80.1 63.4 4.79 p < 0.001 1.022±0.167 PD2
085 0.001
OS-60
MMAE- p=
12 19.9 3.2 1.19 p = 0.024 1.634±0.347 PD1
antibody 0.023
+ All the response measures are defined in Appendix 1
13
Figure Legends:
Figure 1. LRRC15 expression across OS PDX models. (A) Relative mRNA expression of
LRRC15 assessed by RNASeq in 33 OS PDX models. LRRC15 protein expression assessed by
immunohistochemistry in OS models (B) OS9, (C) OS33, and (D) OS60. (E) H-score for the
three models tested
Figure 2: LRRC15 expression (A) across human osteosarcoma tumors from TARGET database
and (B) in comparison to normal tissues
Figure 3: (A) Tumor Growth Inhibition with ABBV-085 across OS PDX models: ABBV-
085 induced significant inhibition in tumor growth in 6/7 of the osteosarcoma models (except
OS9) as compared to vehicle control and 3/7 models (OS1, 33 and 60) as compared to isotype
MMAE, when given once a week for 4 consecutive weeks. The lighter lines represent individual
mice and the bolder lines represent median tumor growth in each group. Two sets of experiments
were performed for OS33. OS-33-1 included control, ABBV-085-6mg/kg and 12 mg/kg and
isotype MMAE 12mg/kg. OS-33-2 included control, ABBV-085-3mg/kg and 6mg/kg and
isotype MMAE at 6mg/kg. (B) Event-free Survival to ABBV-085 across OS PDX models.
ABBV-085 induced significant improvements in event-free survival (EFS) compared to vehicle
(except OS9 and OS42) and isotype MMAE (except OS9 and OS34) control in 5/7 of the
osteosarcoma models tested.
14
Figure 1
A.
200 LRRC 15
150
100
50
0
E.
PDX % Positive
Intensity H-score
Model Tumor Cells
OS9 0 0 0
OS33 2 90 180
OS60 3 100 300
15
Figure 2
A.
B.
16
Figure 3
ABBV-085, antibody-drug conjugate targeting LRRC15, is

effective in osteosarcoma: A report by the Pediatric Preclinical
Testing Consortium
Pooja Hingorani, Michael E. Roth, Yifei Wang, et al.
Mol Cancer Ther Published OnlineFirst December 9, 2020.
Updated version Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-20-0406
Supplementary Access the most recent supplemental material at:

Material http://mct.aacrjournals.org/content/suppl/2020/12/09/1535-7163.MCT-20-0406.DC1
Author Author manuscripts have been peer reviewed and accepted for publication but have not yet been
Manuscript edited.
E-mail alerts Sign up to receive free email-alerts related to this article or journal.
Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Subscriptions Department at pubs@aacr.org.
Permissions To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/early/2020/12/09/1535-7163.MCT-20-0406.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
Rightslink site.

10.1158@1535 7163.MCT 20 0406

Uploaded by

Copyright:

Available Formats

10.1158@1535 7163.MCT 20 0406

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

10.1158@1535 7163.MCT 20 0406

Uploaded by

Copyright:

Available Formats

Author Manuscript Published OnlineFirst on December 9, 2020; DOI: 10.1158/1535-7163.

1. Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX,

Short Running Title- Activity of ABBV-085 in osteosarcoma

Conflict of Interest: The authors have no conflicts to report

several solid tumors including osteosarcoma. ABBV-085, an antibody-drug conjugate against

LRRC15, conjugated to monomethyl auristatin E (MMAE) was studied in osteosarcoma patient

needed to target this disease.

may be an attractive target for drug therapy.

Antibody-drug conjugates (ADC) are a therapeutic strategy in which a cytotoxic payload is

too toxic with systemic administration 6.

as against a multi-drug resistant OS xenograft when administered at dose of 6mg/kg every 4

disease. Two of the 10 OS patients enrolled on study had a PR 10.

Materials and Methods

Pediatric Preclinical Testing Consortium Models

molecular and histologic characterization is in the public domain at PedcBioPortal

LRRC15 expression analysis

of positive cells and calculating an H score as previously described 15.

Treatments (TARGET) database (https://ocg.cancer.gov/programs/target). Further, OS tumor

Genotype-Tissue Expression database (GTEx; https://www.gtexportal.org)

Anderson Cancer Center (ACUF Study #00001656-RN00).

modification of Gehan-Wilcoxon. Objective responses reported as maintained complete

LRRC15 expression in OS PDX models

were calculated for these three models (Figure 1E).

LRRC15 expression in human OS tumors

In vivo efficacy of ABBV-085

comparable levels of activity as ABBV-085 with an MCR suggesting non-specific activity of

testing in remaining models.

compared with the isotype control (Table 2 and Figure 3B).

expression of LRRC15, demonstrated by prolonged EFS and objective responses. LRRC15 is

LRRC15 expressing fibroblasts in tumor microenvironment portend a poor response to immune

additional studies establishing the prevalence of LRRC15 protein expression in OS patient

responses were observed for relapsed refractory undifferentiated pleomorphic sarcoma (2

confirmed partial responses in 10 patients) and for OS (2 confirmed partial responses in 10

normal tissues. If further study of LRRC15 expression in OS tumors confirms a strong

strategy for using the ADC approach to treat OS.

would need to be monitored in preclinical and clinical studies. Nonetheless, identification of

+ All the response measures are defined in Appendix 1

+ All the response measures are defined in Appendix 1

LRRC15 assessed by RNASeq in 33 OS PDX models. LRRC15 protein expression assessed by

three models tested

and (B) in comparison to normal tissues

ABBV-085 induced significant improvements in event-free survival (EFS) compared to vehicle

osteosarcoma models tested.

ABBV-085, antibody-drug conjugate targeting LRRC15, is

Mol Cancer Ther Published OnlineFirst December 9, 2020.

Supplementary Access the most recent supplemental material at:

You might also like